SCHEMBL30748907

SCHEMBL30748907

Oc1cnc(Cl)nc1Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.47
TEK Q02763 1/20 0.47
PIN1 Q13526 6/20 0.46
STK17B O94768 1/20 0.45
STK17A Q9UEE5 1/20 0.45
TTBK1 Q5TCY1 1/20 0.44
TTBK2 Q6IQ55 1/20 0.44
EGFR P00533 3/20 0.44
SCN5A Q14524 1/20 0.44
SCN9A Q15858 1/20 0.44
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
KCNE1 P15382 1/20 0.43
KCNQ1 P51787 1/20 0.43
PTGS2 P35354 1/20 0.41
ERBB2 P04626 1/20 0.41
RIPK2 O43353 1/20 0.41
EPHB2 P29323 1/20 0.41
CTSC P53634 1/20 0.41
SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16684787 0.87 PIN1 (0.57) KDRPIN1STK17AEGFRSYK
SCHEMBL13166189 0.83 STK17A (0.53) KDRTEKPIN1STK17BSTK17A
SCHEMBL30749092 0.83 MEN1 (0.55) KDRTEKPIN1STK17BSTK17A
SCHEMBL30749054 0.83 SMN1; SMN2 (0.51) KDRTEKPIN1STK17BSTK17A
SCHEMBL30749081 0.81 KDR (0.47) KDRTEKPIN1EGFRKCNQ3
SCHEMBL30749000 0.81 KDR (0.42) KDRTEKPIN1STK17BSTK17A
SCHEMBL16684877 0.81 AURKA (0.44) PIN1TTBK1TTBK2EGFR
SCHEMBL31691353 0.80 SMN1; SMN2 (0.48) KDRPIN1EGFRKCNQ3KCNQ2
SCHEMBL30748795 0.78 SYK (0.43) KDRTEKPIN1STK17BSTK17A
SCHEMBL16685087 0.78 AURKA (0.47) KDRPIN1STK17BSTK17AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT KDR 4605/4885TEK 2820/4885PIN1 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.